Proteinase K Market Size, Share & Trends Analysis Report By Form (Lyophilized Powder Form, Liquid Form), By Application (Purification of DNA & RNA, In situ Hybridization, Mitochondria Isolation, Enzyme Removal), By End-Users (Biotechnological Companies, Academic Institutions, Diagnostic Laboratories, Contract Research Organization), By Therapeutic Area (Infectious Diseases, Diabetes, Oncology, Cardiology, Nephrology, Autoimmune Diseases, Neurology, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2022-2030

Market Overview

The global proteinase K market size was valued at USD 70.31 million in 2021, and it is anticipated to reach USD 135.48 million by 2030 at a CAGR of 7.56%.

Tritirachium album Limber produces a broad-spectrum and highly selective serine protease called Proteinase K. By cleaving peptide bonds next to the carboxylic group of aliphatic and aromatic amino acids, Proteinase K aids in the digestion of protein in biological samples. Proteinase K aids in the removal of enzymes that are detrimental to DNA and RNA activity and produces high molecular genomic products by removing the undesired enzymes.

As a result of its capacity to digest native proteins, Proteinase K can be utilized in numerous applications, such as protein fingerprinting, the elimination of nucleases for the purification of protein and preparing chromosomal DNA for pulsed-field gel electrophoresis because of its ability to digest native proteins.

The market for proteinase K is worth a million dollars despite only constituting a small part of the total market for reagents and enzymes. Proteinase K is most frequently utilized in diagnostics laboratories, academic institutes, biotechnology companies, and contract research organizations.

The global market for proteinase K is expected to expand due to various factors. Proteinase K's revenue is expected to soar by the end of the forecast period, thanks mainly to an increase in R&D efforts, lower production costs, a more comprehensive range of uses for Proteinase K, and improved product stability and specificity.

A continuous rise in chronic diseases and better government-backed investment channels to fund advanced research and development are likely to boost the expansion of the global Proteinase K market over the forecasted period.

Market Dynamics

Market drivers

• Funding for r&d in molecular biology

Funding for R&D in molecular biology is likely to promote the growth of the global proteinase K market over the forecast period. For example, in February 2020, Princeton University provided financial support for discovering six research areas. One of these areas of study was creating a novel method to control fat metabolism by creating medications that target an enzyme known as Nocturnal. This enzyme controls how much fat is stored and how much energy is consumed.

• The rising prevalence of chronic diseases

The rising incidence of chronic diseases is the primary factor propelling the expansion of the global market for proteinase K. Chronic diseases are by far the most common form of illness found worldwide. Cancer, diabetes, hypertension, stroke, heart disease, respiratory disorders, arthritis, and obesity are chronic diseases that can result in hospitalization, long-term impairment, a reduction in quality of life, and even death. Chronic diseases include: According to the GLOBOCAN 2020 study, the 5-year prevalence was approximately 50,550,287 globally, and approximately 9,958,133 fatalities were documented globally due to cancer. The increasing incidence of cancer has resulted in an uptick in the number of clinical applications for next-generation sequencing and polymerase chain reaction.

Market opportunities

• Use of proteinase k in the r&d of uncommon diseases

It is anticipated that the utilization of proteinase K in the research and development of uncommon diseases would present participants in the global proteinase K market with a profitable potential opportunity. For example, in April 2019, researchers at Scripps Research reported labeling light chains with fluorophores and coupling shape changes to cleavage by proteinase K to discover a group of small compounds that prevent structural changes to proteins that cause AL amyloidosis, a rare and progressive disease. This research was conducted to identify a group of small molecules that prevent structural changes to proteins that cause AL amyloidosis.

Market restraints

• Proteinase k's low heat stability limits industrial hydrolysis and aminolysis operations.

It is possible that the quality of a protein can be inferred, at least partially, from its degree of purity. Therefore, the purity of the existing Proteinase K on the market and its doping with various other proteins and nucleases are the primary reasons restraining the growth of the Proteinase K market. The limited heat stability of proteinase K restricts the amount of hydrolysis and aminolysis reactions that can occur during industrial production. It limits the expansion of the market throughout the anticipated period.

In addition, the widespread availability of different proteinases and the development of more recent and sophisticated DNA purification methods may hinder the market expansion during the forecast's time covered.

Regional Analysis

According to the region, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and The Middle East & Africa. North America dominates the market.

The US market in recent years has seen a considerable increase in the number of research activities, soaring expenditures on personal healthcare, and increasing use of gene therapy. As a result, North America is the most lucrative regional market for Proteinase K. After North America, the most attractive regions in the global Proteinase K market are APEJ, Western Europe, and other parts of Western Europe. Changing lifestyles, increasing genetic disorders, and increasing accessible disposable money are all projected to contribute to the global Proteinase K market's expansion in the years to come.

Segmental Analysis

The global Proteinase K market share is segmented into five parts based on form, application, end-users, therapeutic area, and region. Further, the form segment is bifurcated into two: Lyophilized Powder Form and Liquid Form. It is predicted that the lyophilized powder form segment will represent a larger revenue share in the global Proteinase K market than the liquid form segment. The rise in the use of lyophilized powder can be ascribed to the growing benefits of powder over liquid for sample storage and preservation.

The market is broken down into Purification of DNA & RNA, In situ Hybridization, Mitochondria Isolation, and Enzyme Removal based on application. Compared to other applications for Proteinase K, purification of DNA & RNA will account for the largest revenue share in the global market.

Based on end-users

The market is divided into Biotechnological Companies, Academic Institutions, Diagnostic Laboratories, and Contract Research organizations. Proteinase K is expected to be in greater demand from biotechnology companies than from other end-users, such as academic institutions and diagnostics laboratories. The fast expansion of the biotechnology industry can be attributed to the increasing usage of Proteinase K in research and development and the discovery of new medicines. The leading cause of Proteinase K's rising use in biotechnology firms is that it is more affordable than other reagents.

Based on therapeutic area

The market is divided into Infectious Diseases, Diabetes, Oncology, Cardiology, Nephrology, Autoimmune Diseases, Neurology, and Others. Due to the rising frequency of infectious diseases and the widespread use of proteinase K in diagnosing various infectious diseases, the infectious diseases segment is found to dominate the proteinase K market.

According to the region, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and The Middle East & Africa. North America dominates the market.

Recent Developments

• May 2022, one of the world's largest suppliers of diagnostic testing and life science raw materials, Meridian Bioscience Inc., has purchased most of EUPROTEIN Inc.'s assets through its subsidiary Meridian Life Science, Inc. The deal came to an end on April 30th, 2022.

• February 2022, the LyoPrime Luna Probe One-Step RT-qPCR Mix with UDG is the first lyophilized product made by Fluorogenics to be released by New England Biolabs (NEB®).